Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Scandinavian Journal of Gastroenterology

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/00365521.2010.513060PMID 20799911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.

  2009cited by this paper
• Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

  2008cited by this paper
• Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1.

  2008cited by this paper
• Role of Myosin Va in the Plasticity of the Vertebrate Neuromuscular Junction In Vivo

  2008cited by this paper
• Dependence of TIMP-1 Plasma Levels on Preanalytical Specimen Handling

  2008cited by this paper
• Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers*

  2008cited by this paper
• Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer

  2008cited by this paper
• Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment

  2008cited by this paper
• Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection

  2008influential reference
• Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review

  2007cited by this paper
• Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.

  2007cited by this paper
• Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1)

  2007cited by this paper
• TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid

  2007cited by this paper
• Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.

  2006cited by this paper
• ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

  2006cited by this paper
• Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test

  2006cited by this paper
• Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.

  2006cited by this paper
• Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer

  2006cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2006cited by this paper
• Serum Mannan-Binding Lectin-Associated Serine Protease 2 Levels in Colorectal Cancer: Relation to Recurrence and Mortality

  2005cited by this paper
• Noninvasive Testing for Colorectal Cancer: A Review

  2005cited by this paper
• A National Survey of Primary Care Physicians' Methods for Screening for Fecal Occult Blood

  2005cited by this paper
• Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales.

  2005cited by this paper
• Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation

  2005cited by this paper
• Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.

  2005cited by this paper
• Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.

  2005cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Colon cancer screening in 2005: status and challenges.

  2005cited by this paper
• Plasma Levels of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-1 Correlate With Disease Stage and Survival in Colorectal Cancer Patients

  2005influential reference
• Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing

  2005cited by this paper
• Evaluation of analytical methods and workflow performance of the Architect ci8200 integrated serum/plasma analyzer system.

  2005cited by this paper
• Rules of evidence for cancer molecular-marker discovery and validation

  2004cited by this paper
• Colorectal cancer screening and treatment: review of outcomes research.

  2004cited by this paper
• Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds

  2004cited by this paper
• Evaluation of Sample Handling in Relation to Levels of Tissue Inhibitor of Metalloproteinases-1 Measured in Blood by Immunoassay

  2003cited by this paper
• Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.

  2002cited by this paper
• Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.

  2002cited by this paper
• Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.

  2002influential reference
• Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies

  2002cited by this paper
• Biomarkers for early detection of colon cancer.

  2001cited by this paper
• Peripheral blood level alterations of TIMP‐1, MMP‐2 and MMP‐9 in patients with Type 1 diabetes

  2001cited by this paper
• High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

  2000cited by this paper
• Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

  1999cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• Randomised study of screening for colorectal cancer with faecal-occult-blood test.

  1996cited by this paper
• Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

  1989cited by this paper

• Evaluation of a research use only (RUO) TIMP-1 assay for use with the automated Alinity i platform.

  2026cites this paper
• Integration of Machine Learning Algorithms and Single‐Cell Sequencing Analysis Reveals the Efferocytosis‐Related Molecular Subtype and Prognostic Scoring Index in Colon Adenocarcinoma

  2025cites this paper
• Plasma matrix metalloproteinases 7 and 8 and tissue inhibitor of metalloproteinases 1 as prognostic biomarkers in colorectal cancer

  2025cites this paper
• Dual immunoplatform to assess senescence biomarkers TIMP-1 and GDF-15: Advancing in the understanding of colorectal cancer

  2024cites this paper
• Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review

  2024cites this paper
• Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.

  2023cites this paper
• Colorectal cancer diagnostic biomarkers: Beyond faecal haemoglobin.

  2023cites this paper
• Investigating The variations in The expression level of CEA and TIMP-1 markers in Human Colorectal Carcinoma in Egyptian Patient

  2022cites this paper
• Future of Colorectal Cancer Screening: From One-Size-FITs-All to Tailor-Made

  2022cites this paper
• Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancy.

  2022cites this paper
• Liquid biopsy: the value of different bodily fluids.

  2022cites this paper
• Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Lower Gastrointestinal Cancers: A Systematic Review and Meta-Analysis

  2021cites this paper
• Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer

  2021cites this paper
• CEG_A_251633 273..284

  2020cites this paper
• Early Detection and Recurrence of Colorectal Adenomas by Combination of Eight Cancer-Associated Biomarkers in Plasma

  2020cites this paper
• Labordiagnostik/Tumormarker: Was ist sinnvoll/effektiv, was wird kommen?

  2020cites this paper
• The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence

  2020cites this paper
• Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

  2020cites this paper
• HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma

  2019cites this paper
• A Review of the Role of Carcinoembryonic Antigen in Clinical Practice

  2019cites this paper
• Role of Cellular Biomolecules in Screening, Diagnosis, and Treatment of Colorectal Cancer.

  2019cites this paper
• Tumor Markers in GI and HPB Cancers

  2019cites this paper
• GI Surgery Annual

  2019cites this paper
• Tissue inhibitor of metalloproteinase-1

  2019cites this paper
• Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients

  2018cites this paper
• Triage for selection to colonoscopy?

  2018cites this paper
• Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?

  2018cites this paper
• TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis

  2018cites this paper
• Plasma miRNA can detect colorectal cancer, but how early?

  2018cites this paper
• Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?

  2018cites this paper
• A hierarchical classifier based on human blood plasma fluorescence for non-invasive colorectal cancer screening

  2017cites this paper
• Proteomic profiling of human plasma for cancer biomarker discovery

  2017cites this paper
• Published diagnostic models safely excluded colorectal cancer in an independent primary care validation study.

  2017cites this paper
• Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.

  2017cites this paper
• Detection of colorectal neoplasia: Combination of eight blood‐based, cancer‐associated protein biomarkers

  2017influential citation
• Syddansk Universitet TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells A potential novel approach to the treatment of metastatic colorectal cancer

  2016cites this paper
• Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers

  2016cites this paper
• Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

  2016cites this paper
• TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer

  2016cites this paper
• Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9Me3

  2016cites this paper
• Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer†

  2016cites this paper
• Increased serological cancer-associated biomarkers and risk of development of primary malignancy after large bowel endoscopy

  2016cites this paper
• Discovery and Validation of Plasma-Protein Biomarker Panels for the Detection of Colorectal Cancer and Advanced Adenoma in a Danish Collection of Samples from Patients Referred for Diagnostic Colonoscopy.

  2016cites this paper
• University of Southern Denmark TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells A potential novel approach to the treatment of metastatic colorectal cancer

  2016cites this paper
• University of Southern Denmark Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients Aaberg-Jessen,

  2016cites this paper
• Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients

  2016cites this paper
• Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.

  2015cites this paper
• Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies

  2015cites this paper
• The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study

  2015cites this paper
• Role of Irradiated Tumor Cell Lysate Vaccine and Low Doses of Gamma Irradiation in Tumor Regression

  2015cites this paper
• A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers

  2015cites this paper
• Detection of AKR1B10 in Peripheral Blood by Anti-AKR1B10-Conjugated CdTe/CdS Quantum Dots.

  2015cites this paper
• Transforming growth factor-β, MAPK and Wnt signaling interactions in colorectal cancer

  2015cites this paper
• Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

  2014cites this paper
• MECHANISMS OF TUMOR PROGRESSION

  2014cites this paper
• Impact of proteolytic enzymes in colorectal cancer development and progression.

  2014cites this paper
• Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer

  2014cites this paper
• Management of colorectal cancer and diabetes

  2014cites this paper
• Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

  2014cites this paper
• Differences in carcinoembryonic antigen levels between colon and rectal cancer.

  2014cites this paper
• Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.

  2014cites this paper
• Evaluation of complement proteins as screening markers for colorectal cancer

  2014cites this paper
• Diagnostic strategies in patients with lower abdominal complaints in primary care

  2014cites this paper
• Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients

  2014cites this paper
• Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

  2014cites this paper
• [New era of laboratory testing. Topics: II. Particulars 4. Topics in tumor marker testing].

  2013cites this paper
• Serological Markers of Digestive Tract Cancers

  2013cites this paper
• 4. Topics in Tumor Marker Testing

  2013cites this paper
• Early detection of recurrence after curative resection for colorectal cancer – obstacles when using soluble biomarkers?

  2013cites this paper
• Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals

  2013influential citation
• Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA)

  2013cites this paper
• The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer

  2012cites this paper
• Data fusion in metabolomic cancer diagnostics

  2012cites this paper
• Plasma TIMP1 level is a prognostic factor in patients with liver metastases.

  2012cites this paper
• Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients

  2012cites this paper
• Serum MMP‐8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors

  2012cites this paper
• Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study

  2012cites this paper
• Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and Prognosis

  2012cites this paper
• Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening

  2012cites this paper
• Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material*

  2011cites this paper
• Screening for colorectal cancer: possible improvements by risk assessment evaluation?

  2011influential citation
• This month in the Scandinavian Journal of Gastroenterology

  2011cites this paper
• Detection and clinical significance of DLC1 gene methylation in serum DNA from colorectal cancer patients

  2011influential citation
• Efficiency of diagnostic biomarkers among colonic schistosomiasis Egyptian patients.

  2011cites this paper
• Proteome alteration in human colon cancer cells by the treatment of HangAmDan-B

  2011cites this paper